ScreenerHero

ONCYOncolytics Biotech Inc.

NAS · US · Healthcare · Biotechnology · oncolyticsbiotech.com
0.8431USDMkt Cap: 107.50M $P/E: —

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunot…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap107.50M $
Enterprise Value98.56M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.76M $
Revenue/Share—
Last Price0.8431 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.30
PEG—
EV/EBITDA-2.62
EV/Revenue—
P/S—
P/B-18.22
EPS (TTM)-0.35
EPS (Forward)-0.24
52W Range
0.800088% of range0.8492
52W High0.8492 USD
52W Low0.8000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE757.02%
ROA-379.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.11M $
CapEx (TTM)6.00K $
FCF Margin—
FCF Yield-11.17%
Net Debt-3.67M $
Net Debt/EBITDA0.10
Balance Sheet
Debt/Equity-0.15
Current Ratio1.35
Quick Ratio1.02
Book Value/Sh-0.0440 USD
Cash/Share0.0320 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 25, 2018
Splits
Last Split10:95
Split DateMay 25, 2018
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.278 USD
Upside (mean)+407.4%
Target Range2.940 USD – 6.114 USD
$2.940+407.4% to mean$6.114
# Analysts6
Ownership
Shares Out.127.51M
Float124.88M
Insiders2.05%
Institutions3.31%
Short Interest
Short Ratio5.5d
Short % Float7.03%
Short % Out.6.89%
Shares Short8.23M
Short (prev mo.)6.61M
Technical
SMA 500.8536 (-1.2%)
SMA 2000.9467 (-10.9%)
Beta1.14
S&P 52W Chg21.00%
Avg Vol (30d)538.83K
Avg Vol (10d)697.26K
Technical Indicators
RSI (14)53.4
MACD-0.0051
MACD Signal-0.0119
MACD Hist.+0.0068
BB Upper0.8569 USD
BB Middle0.8017 USD
BB Lower0.7464 USD
BB Width13.79%
ATR (14)0.0467 USD
Vol Ratio (20d)0.73x